4.6 Review

The immunosuppressive and pro-tumor functions of CCL18 at the tumor microenvironment

Journal

CYTOKINE & GROWTH FACTOR REVIEWS
Volume 60, Issue -, Pages 107-119

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2021.03.005

Keywords

Tumor microenvironment; Chemokine; Biomarker; Immunosuppressive; Cancer; Therapeutic target

Funding

  1. Portuguese funds through FCT - Fundacao para a Ciencia e a Tecnologia (FCT) /Ministerio da Ciencia, Tecnologia e Ensino Superior [UID/BIM/04293/2019]
  2. FCT [PTDC/BTM-SAL/31859/2017, SFRH/BD/147526/2019, CENTRO010145FEDER030013, POCI010145FEDER030034, DL 57/2016/CP1360/CT0009]
  3. FCT, Portugal [PTDC-BIA-CEL/31743/2017]
  4. Common Fund of the Office of the Director of the National Institutes of Health
  5. NCI
  6. NHGRI
  7. NHLBI
  8. NIDA
  9. NIMH
  10. NINDS
  11. Fundação para a Ciência e a Tecnologia [PTDC/BTM-SAL/31859/2017, PTDC/BIA-CEL/31743/2017, SFRH/BD/147526/2019, DL 57/2016/CP1360/CT0009] Funding Source: FCT

Ask authors/readers for more resources

CCL18 is an important chemokine in the tumor microenvironment, playing a key role in promoting tumor progression. Although there is potential for it to be used as a biomarker or therapeutic target, its functions in the context of cancer are still poorly explored.
Chemokines are essential mediators of immune cell trafficking. In a tumor microenvironment context, chemotactic cytokines are known to regulate the migration, positioning and interaction of different cell subsets with both anti- and pro-tumor functions. Additionally, chemokines have critical roles regarding non-immune cells, highlighting their importance in tumor growth and progression. CCL18 is a primate-specific chemokine produced by macrophages and dendritic cells. This chemokine presents both constitutive and inducible expression. It is mainly associated with a tolerogenic response and involved in maintaining homeostasis of the immune system under physiological conditions. Recently, CCL18 has been noticed as an important component of the complex chemokine system involved in the biology of tumors. This chemokine induces T regulatory cell differentiation and recruitment to the tumor milieu, with subsequent induction of a pro-tumor (M2-like) macrophage phenotype. CCL18 is also directly involved in cancer cell-invasion, migration, epithelial-to-mesenchymal transition and angiogenesis stimulation, pinpointing an important role in the promotion of cancer progression. Interestingly, this chemokine is highly expressed in tumor tissues, particularly at the invasive front of more advanced stages (e.g. colorectal cancer), and high levels are detected in the serum of patients, correlating with poor prognosis. Despite the promising role of CCL18 as a biomarker and/or therapeutic target to hamper disease progression, its pleiotropic functions in a context of cancer are still poorly explored. The scarce knowledge concerning the receptors for this chemokine, together with the insufficient insight on the downstream signaling pathways, have impaired the selection of this molecule as an immediate target for translational research. In this Review, we will discuss recent findings concerning the role of CCL18 in cancer, integrate recently disclosed molecular mechanisms and compile data from current clinical studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available